Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database

Hepatology

Volumn 68, Issue 6, 2018, Pages 2230-2238

  Allen, Alina M ^a   Van Houten, Holly K ^a,b   Sangaralingham, Lindsey R ^a,b   Talwalkar, Jayant A ^a   McCoy, Rozalina G ^a  

^a MAYO CLINIC   (United States)

^b OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; EMERGENCY WARD; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATOGRAPHY; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LABORATORY TEST; LIVER BIOPSY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICARE; METABOLIC DISORDER; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TRANSIENT ELASTOGRAPHY; ULTRASOUND; UNITED STATES; VERY ELDERLY; ECONOMICS; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85053706797     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.30094     Document Type: Article

References (26)

1. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577-1586
2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131
3. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-654
4. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-2273
5. Allen AM, Terry TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology 2018;67:1726-1736
6. Adams LA, Lymp JF, St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121
7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419
8. Fuchs VR. How and why US health care differs from that in other OECD countries. JAMA 2013;309:33-34
9. Hartman M, Martin AB, Espinosa N, Catlin A, The National Health Expenditure Accounts Team. National health care spending in 2016: spending and enrollment growth slow after initial coverage expansions. Health Aff (Millwood) 2018;37:150-160
10. Younossi ZM, Zheng L, Stepanova M, Henry L, Venkatesan C, Mishra A. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. JClin Gastroenterol 2015;49:222-227
11. Sayiner M, Otgonsuren M, Cable R, Younossi I, Afendy M, Golabi P, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. JClin Gastroenterol 2017;51:254-260
12. Optum. https://www.optumlabs.com/. Accessed February 6, 2018
13. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 2014;33:1187-1194
14. Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. JManag Care Spec Pharm 2017;23:633-641
15. Brady BL, Tkacz J, Meyer R, Bolge SC, Ruetsch C. Assessment of rheumatoid arthritis quality process measures and associated costs. Popul Health Manag 2017;20:31-40
16. Weaver J, Sajjan S, Lewiecki EM, Harris ST, Marvos P. Prevalence and cost of subsequent fractures among U.S. patients with an incident fracture. JManag Care Spec Pharm 2017;23:461-471
17. Department of Labor Bureau of Labor Statistics. Consumer Price Index: chained consumer price index for all urban consumers (C-CPI-U). Washington, DC; 2017
18. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-133
19. Polanco-Briceno S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res Notes 2016;9:157
20. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-357
21. Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. PLoS One 2016;11:e0147237
22. Costhelper. http://health.costhelper.com. Accessed January 9, 2018
23. Wright AP, Desai AP, Bajpai S, King LY, Sahani DV, Corey KE. Gaps in recognition and evaluation of incidentally identified hepatic steatosis. Dig Dis Sci 2015;60:333-338
24. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 2016;63:138-147
25. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544-563
26. Elshaug AG, Rosenthal MB, Lavis JN, Brownlee S, Schmidt H, Nagpal S, et al. Levers for addressing medical underuse and overuse: achieving high-value health care. Lancet 2017;390:191-202